Myeloma Paper of the Day, May 16th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: DESCAR-T registry of French patients getting idecabtagene vicleucel CAR T for relapsed/refractory myeloma finds best ORR and ≥CR rates were 88% and 47%, respectively; median PFS was 12.5 months, and median OS was 20.8 months.”
Source: Robert Orlowski/X
Authors: B. Ferment, J. Lambert, D. Caillot, I. Lafon, L. Karlin, A. Lazareth, C. Touzeau, X. Leleu, N. Moya, S. Harel, A. Perrot, P. Bories, L. Vincent, S. Lamure, M. Mohty, F. Malard, S. Manier, I. Yakoub-Agha, J.-M. Schiano De Colella, G. Brisou, A. Talbot, O. Decaux, R. Houot, S. Le Gouill, N. Bigot, T. Facon, J. Corre, P. Moreau, B. Arnulf
Other insights by Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023